Description
General description
HybridSPE-Phospholipid technology is a simple and generic sample prep platform designed for the gross level removal of endogenous protein and phospholipid interferences from biological plasma and serum prior to LC-MS or LC-MS/MS analysis. Biological plasma or serum is first subjected to protein precipitation via the addition and mixing of acidified acetonitrile. Precipitated proteins are then removed by centrifugation and the resulting supernatant is loaded on the HybridSPE-Phospholipid 96-well plate or cartridge which acts as a chemical filter that specifically targets the removal of endogenous sample phospholipids. The phospholipid retention mechanism is based on a highly selective Lewis acid-base interaction between the proprietary zirconia ions functionally bonded to the HybridSPE-Phospholipid stationary phase and the phosphate moiety consistent with all phospholipids. The resulting eluent is ready for immediate LC-MS or LC-MS-MS analysis.
The "In-well" and "In-cartridge" precipitation methods are available for the HybridSPE-Phospholipid 96-well version and HybridSPE-Phospholipid Ultra cartridge in which biological plasma/serum is first added to either the well or cartridge, followed by acidified acetonitrile (precipitation agent). After a brief mixing/vortexing step, vacuum is applied. Because the 96-well and Ultra cartridge versions contain a series of low porosity hydrophobic filters/frits, the packed-bed filter/frit assembly acts as a depth filter facilitating the concurrent removal of both phospholipids and precipitated proteins during the extraction process. Standard HybridSPE-Phospholipid cartridges require an "off-line" precipitation method.
Application
Rapid analysis of 65 pharmaceuticals and 7 personal care products in plasma and whole-body tissue samples of fish using acidic extraction, zirconia-coated silica cleanup, and liquid chromatography-tandem mass spectrometry: This study discusses the advanced application of chromatography and mass spectrometry, which could involve the use of technologies like HybridSPE®-Phospholipid for sample preparation, specifically for rapid analysis in biological matrices (Tanoue et al., 2020).
Multi LC-MS/MS and LC-HRMS Methods for Determination of 24 Mycotoxins including Major Phase I and II Biomarker Metabolites in Biological Matrices from Pigs and Broiler Chickens: Demonstrates how LC-MS/MS, potentially incorporating HybridSPE®-Phospholipid technology for sample cleanup, facilitates the sensitive and accurate detection of mycotoxins in complex biological samples (Lauwers et al., 2019).
Evaluation of an Ion Trap Toxtyper Liquid Chromatography With An Ion Trap Mass Spectrometric Instrument (Toxtyper) for Drug of Abuse Screening in Oral Fluid: Explores the utility of specific LC-MS/MS methodologies which could integrate HybridSPE®-Phospholipid for bioanalytical sample cleanup, enhancing drug screening accuracy (Plecko et al., 2018).
Effective phospholipid removal from plasma samples by solid phase extraction with the use of copper (II) modified silica gel cartridges: This research potentially aligns with the use of HybridSPE®-Phospholipid technologies for phospholipid removal, focusing on enhancing the purity and quality of chromatography samples (Flieger et al., 2017).
Liquid chromatography mass spectrometry determination of perfluoroalkyl acids in environmental solid extracts after phospholipid removal and on-line turbulent flow chromatography purification: Illustrates a specialized application of chromatography and mass spectrometry where HybridSPE®-Phospholipid could be applied to improve the analysis of environmental samples by efficient phospholipid removal (Mazzoni et al., 2016).
Features and Benefits
Merges the simplicity of protein precipitation and the selectivity of SPE via the targeted removal of phospholipids
Reduce ion-suppression through the complete removal of phospholipids and precipitated proteins
2-3 step generic procedure
Minimal to no method development
Available in 96-well and 1 mL cartridge dimensions
Legal Information
HybridSPE is a registered trademark of Merck KGaA, Darmstadt, Germany
